Blockchain Registration Transaction Record

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

Quantum BioPharma submits Lucid-MS to UK's ILAP program, aiming to accelerate access to groundbreaking MS treatment. Learn more about this innovative approach.

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

This development is crucial for the millions affected by multiple sclerosis worldwide, offering hope for a faster route to innovative treatments. Quantum BioPharma's submission to the ILAP program represents a potential leap forward in MS therapy, emphasizing the importance of streamlined regulatory processes in bringing life-changing medications to patients sooner. The progress of Lucid-MS could significantly impact the treatment landscape for MS, showcasing the value of strategic partnerships and regulatory innovation in healthcare.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x5aafd8cc592d80a4363511dc0d0e6ab620e8f6efa40064d7bec15c67de455c1a
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintovalhQma-0b70ed68017ee5aa45ffc081b961cfe6